FSD Pharma’s Stock Doubles, Biotech Company Fighting COVID-19

After FSD Pharma’s announcing an old drug test for COVID-19 treatment NASDAQ: HUGE tripled and now being traded at $8.78 with an increased volume of 12,009,662 shares.

FSD Pharma is a tiny biotech company like any other healthcare-related firm that strives in the race to create effective COVID-19 treatment technology; whether it is a device or vaccine. That old medicine that will go under testing is called ultramicronized PEA, made and sold in Europe in the 1970’s as a treatment for flu and cold. Except in Italy and Spain FSD owns rights to PEA worldwide. The drug belongs to another company that sells PEA as a medical food supplement in Spain and Italy.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life

Alex Krakowsky has 979 posts and counting. See all posts by Alex Krakowsky